Pharmacokinetics and pharmacodynamics of different modes of insulin pump delivery. A randomized, controlled study comparing subcutaneous and intravenous administration of insulin aspart

Diabetic Medicine

Volumn 28, Issue 2, 2011, Pages 230-236

  Ihlo, C A ^a   Lauritzen, T ^b   Sturis, J ^c   Skyggebjerg, O ^d   Christiansen, J S ^a   Laursen, T ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c Histology and Delivery ^*  (Denmark)

^d NOVO NORDISK A S   (Denmark)

Author keywords

Bioavailability; Insulin aspart; Insulin pharmacodynamics; Insulin pharmacokinetics; Insulin pump therapy

Indexed keywords

GLUCOSE; INSULIN ASPART;

ADULT; ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INTERMETHOD COMPARISON; MALE; RANDOMIZED CONTROLLED TRIAL;

ADULT; BIOLOGICAL AVAILABILITY; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; MALE;

EID: 78651070550     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2010.03149.x     Document Type: Article

References (17)

1. Lauritzen T. Pharmacokinetic and clinical aspects of intensified subcutaneous insulin therapy. Dan Med Bull 1985; 32: 104-118.
2. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analogue insulin aspart. Diabetes Care 1998; 21: 1910-1914.
3. Lauritzen T, Pramming S, Deckert T, Binder C. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia 1983; 24: 326-329.
4. Heinemann L, Nosek L, Kapitza C, Schweitzer M-A, Krinelke L. Changes in basal insulin infusion rates with CSII: time until a change in metabolic effect is induced in patients with Type 1 diabetes. Diabetes Care 2009; 32: 1437-1439.
5. Mosekilde E, Jensen KS, Binder C, Pramming S, Thorsteinsson B. Modeling absorption kinetics of subcutaneous injected soluble insulin. J Pharmacokinet Biopharm 1989; 17: 67-87.
6. Howey DC, Browsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402.
7. TM): sensitive, broadly applicable homogeneous immunoassay method. Clin Chem 1996; 42: 1518-1526.
8. Petersen SB, Lovmand JM, Honoré L, Jeppesen CB, Pridal L, Skyggebjerg O. Comparison of a luminiscent oxygen channeling immunoassay and an ELISA for detecting insulin aspart in human serum. J Pharm Biomed Anal 2010; 51: 217-224.
9. Heinemann L, Traut T, Heise T. Time-action profile of inhaled insulin. Diabet Med 1997; 14: 63-72.
10. Jansson PA, Fowelin JP, von Schenck HP, Smith UP, Lönnroth PN. Measurement by microdialysis of the insulin concentration in subcutaneous interstitial fluid. Importance of the endothelial barrier for insulin. Diabetes 1993; 42: 1469-1473.
11. Stevenson RW. Subcutaneous degradation of insulin. Diabetologia 1982; 22: 221-222.
12. Paulsen EP, Courtney JW, Duckworth WC. Insulin resistance caused by massive degradation of subcutaneous insulin. Diabetes 1979; 28: 640-645.
13. Lauritzen T, Pramming S, Deckert T, Binder C. Pharmacokinetics of continuous subcutaneous insulin infusion. Diabetologia 1983; 24: 326-329.
14. Nelson JD, Marliss EB, Albisser AM, Zinman B. Role of continuous component in subcutaneous » open-loop « insulin delivery. Lancet 1980; i: 1383-1386.
15. Rizza RA, Gerich JE, Haymond MW, Westland RE, Hall LD, Clemens AH et al. Control of blood sugar in insulin-dependent diabetes: comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion, and intensified conventional insulin therapy. N Engl J Med 1980; 303: 1313-1318.
16. Home PD, Barriocanal LA, Lindholm A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 1999; 55: 199-203.
17. Lindholm A, McEwen J, Riis A. Improved postprandial glycemic control with insulin aspart. Diabetes Care 1999; 22: 801-805.